Chan Henry Lee Sells 2,666 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 2,666 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total transaction of $959,760.00. Following the completion of the sale, the senior vice president directly owned 812 shares in the company, valued at $292,320. This trade represents a 76.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Thursday, July 30th, Chan Henry Lee sold 1,044 shares of BeOne Medicines stock. The stock was sold at an average price of $323.69, for a total transaction of $337,932.36.
• On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total transaction of $200,833.44.
• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total value of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.

BeOne Medicines Stock Down 2.4%

NASDAQ:ONC opened at $347.48 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22. The stock’s fifty day moving average is $304.47 and its two-hundred day moving average is $309.51. The stock has a market capitalization of $38.13 billion, a price-to-earnings ratio of 61.18 and a beta of 0.49. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ONC. Leerink Partners increased their price target on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $402.14.

Institutional Trading of BeOne Medicines

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in shares of BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after purchasing an additional 97,244 shares during the last quarter. Renaissance Technologies LLC purchased a new position in BeOne Medicines in the first quarter valued at $19,438,000. SEB Asset Management AB acquired a new stake in BeOne Medicines in the first quarter valued at $16,653,000. Rokos Capital Management LLP acquired a new stake in BeOne Medicines in the first quarter valued at $4,256,000. Finally, Generali Investments Management Co LLC acquired a new stake in BeOne Medicines in the second quarter valued at $2,280,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.